Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Bioreliance Ltd.
EIR
•Bioreliance Ltd.•September 27, 2019

Bioreliance Ltd. – FDA EIR, Sep 27, 2019

Record Details

An FDA routine surveillance inspection of BioReliance Limited, a contract testing laboratory and active pharmaceutical ingredient (API) manufacturer in Glasgow, United Kingdom, was conducted from September 23 to 27, 2019. The inspection assessed the company's adherence to current Good Manufacturing Practices (cGMP), governed by 21 CFR Parts 210 and 211, and relevant compliance programs for drugs and biologics. The inspection identified three significant observations, issued on an FDA Form 483. Firstly, the company failed to consistently follow written sanitation procedures for cleaning and maintaining manufacturing equipment, specifically biosafety cabinets. This was a repeat observation, with video evidence showing incomplete cleaning, such as neglecting glass visors. Secondly, aseptic simulation studies (media fills) used for operator qualification were found to be deficient. They did not accurately represent routine production conditions, particularly regarding the number of personnel involved in aseptic filling, despite a previous corrective action requiring additional operators. Thirdly, changes or repairs to critical equipment, such as the installation of a peristaltic pump on HVAC units to address condensation, were performed without adequate review by the quality unit through a formal change control process. BioReliance management acknowledged the observations, indicating their understanding and commitment to providing a written response to the agency, which was subsequently received on October 17, 2019. The findings highlight areas where improved adherence to established procedures, more realistic aseptic process simulations, and robust quality oversight of equipment modifications are necessary to ensure product quality and patient safety.

Company
Bioreliance Ltd.
Inspection date
September 27, 2019
Product type
biologics
Office
Office of Regulatory Affairs
Person
  • Joey V. Quitania (Public Affairs Specialist)
View Company Profile

ID · 3c24bf4a-1400-4924-9a48-479ed85a811e

Violation Codes4
21 CFR 820.19821 CFR 21121 CFR 820.10021 CFR 210

Full citation text and observation details available on the Dashboard.

Other documents for Bioreliance Ltd.
  • 483 - 2025-12-05December 5, 2025
  • 483 - 2019-09-27September 27, 2019
  • EIR - 2019-03-15March 15, 2019
  • EIR - 2017-09-22September 22, 2017
  • 483 - 2016-03-23March 23, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bioreliance Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.